Evaluation of an integrated care pathway for out-of-hospital treatment of older adults with an acute moderate-to-severe lower respiratory tract infection or pneumonia

Haga Hospital0 sites300 target enrollmentNovember 28, 2022

Overview

2023 Protocol article in https://doi.org/10.1136/bmjopen-2023-073126 (added 18/08/2023)

Registry

who.int

Start Date

November 28, 2022

End Date

November 30, 2024

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Haga Hospital

•Current inclusion criteria as of 18/07/2023:
•To be eligible to participate in this study, a patient must meet all of the following criteria:
•1\. Age \=65 years
•2\. Clinical diagnosis of an acute moderate\-to\-severe (Pneumonia Severity Index (PSI) class \=3 or CURB\-65 \=2\) lower respiratory tract infection or pneumonia
•3\. Oxygen saturation \=92% and respiratory rate \=24/minute with maximum five litres of oxygen (or adjusted oxygen saturation cut\-offs as clinically indicated (e.g. for patients with chronic obstructive pulmonary disease (COPD)) by the treating physician)
•4\. Written informed consent (IC) for participation in the study
•To be eligible to participate in this study, an informal caregiver must meet all of the following criteria:
•1\. Age \=18 years
•2\. Being an informal caregiver of a patient included in the study
•3\. Written IC for participation in the study

•Current exclusion criteria as of 18/07/2023:
•A potential patient who meets any of the following criteria will not be able to participate:
•1\. Chemotherapy for solid organ malignancy (\<2 months before presentation)
•2\. Active hematologic malignancy
•3\. Immunocompromised status (e.g. solid organ transplants)
•4\. Severe dementia (Clinical Dementia Rating Scale Sum of Boxes (CDR\-SOB) score 16\-18\)
•Previous exclusion criteria:
•A potential patient who meets any of the following criteria will not be able to participate:
•1\. Patients receiving chemotherapy (\<2 months before presentation)
•2\. Patients with active hematologic malignancy